Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioCardia, Inc. stock logo
BCDA
BioCardia
$2.07
+5.1%
$2.29
$1.63
$5.69
$10.72M0.91290,085 shs50,753 shs
Dyadic International, Inc. stock logo
DYAI
Dyadic International
$0.94
-5.6%
$1.19
$0.93
$2.67
$28.29M1.0168,641 shs53,526 shs
Outlook Therapeutics, Inc. stock logo
OTLK
Outlook Therapeutics
$1.61
+0.6%
$1.46
$0.87
$9.25
$54.04M0.39762,195 shs763,620 shs
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
$3.39
+9.4%
$5.25
$2.67
$33.90
$19.63M0.7398,852 shs202,062 shs
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioCardia, Inc. stock logo
BCDA
BioCardia
+5.08%+5.61%+5.08%-2.82%-60.12%
Dyadic International, Inc. stock logo
DYAI
Dyadic International
-5.60%-11.32%-20.34%-30.88%-51.79%
Outlook Therapeutics, Inc. stock logo
OTLK
Outlook Therapeutics
+0.63%-5.29%+5.23%+7.33%-79.62%
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
+9.35%+25.09%+1,684.21%-72.22%-87.49%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
BioCardia, Inc. stock logo
BCDA
BioCardia
2.8189 of 5 stars
3.83.00.00.02.12.50.6
Dyadic International, Inc. stock logo
DYAI
Dyadic International
2.8867 of 5 stars
3.55.00.00.03.31.70.0
Outlook Therapeutics, Inc. stock logo
OTLK
Outlook Therapeutics
1.7397 of 5 stars
3.43.00.00.01.90.00.6
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
4.5709 of 5 stars
3.54.00.04.63.03.30.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BioCardia, Inc. stock logo
BCDA
BioCardia
3.50
Strong Buy$25.001,107.73% Upside
Dyadic International, Inc. stock logo
DYAI
Dyadic International
3.00
Buy$6.00538.30% Upside
Outlook Therapeutics, Inc. stock logo
OTLK
Outlook Therapeutics
2.80
Moderate Buy$10.20533.54% Upside
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
3.00
Buy$72.332,033.73% Upside

Current Analyst Ratings Breakdown

Latest BCDA, XFOR, DYAI, and OTLK Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/20/2025
Outlook Therapeutics, Inc. stock logo
OTLK
Outlook Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
5/2/2025
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$1.50 ➝ $7.00
3/27/2025
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$45.00 ➝ $45.00
3/26/2025
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$90.00 ➝ $90.00
(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BioCardia, Inc. stock logo
BCDA
BioCardia
$3K3,572.82N/AN/A($1.11) per share-1.86
Dyadic International, Inc. stock logo
DYAI
Dyadic International
$3.34M8.46N/AN/A$0.20 per share4.70
Outlook Therapeutics, Inc. stock logo
OTLK
Outlook Therapeutics
N/AN/AN/AN/A($1.57) per shareN/A
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
$31.36M0.63N/AN/A$0.31 per share10.94
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BioCardia, Inc. stock logo
BCDA
BioCardia
-$11.57M-$2.33N/AN/AN/A-1,999.77%N/A-208.38%8/12/2025 (Estimated)
Dyadic International, Inc. stock logo
DYAI
Dyadic International
-$6.80M-$0.20N/AN/AN/A-188.09%-149.16%-59.81%8/12/2025 (Estimated)
Outlook Therapeutics, Inc. stock logo
OTLK
Outlook Therapeutics
-$75.37M-$0.91N/AN/AN/AN/AN/A-225.12%8/13/2025 (Estimated)
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
-$101.17M$2.14N/AN/AN/AN/A-236.19%-75.14%8/14/2025 (Estimated)

Latest BCDA, XFOR, DYAI, and OTLK Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q2 2025
Outlook Therapeutics, Inc. stock logo
OTLK
Outlook Therapeutics
-$0.55-$0.40+$0.15-$1.50$0.70 millionN/A
5/14/2025Q1 2025
BioCardia, Inc. stock logo
BCDA
BioCardia
-$0.39-$0.59-$0.20-$0.59N/AN/A
5/14/2025Q1 2025
Dyadic International, Inc. stock logo
DYAI
Dyadic International
N/A-$0.07N/A-$0.07N/A$0.39 million
5/1/2025Q1 2025
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
-$4.13$0.04+$4.17$0.04$7.03 million$28.81 million
3/26/2025Q4 2024
BioCardia, Inc. stock logo
BCDA
BioCardia
-$0.87-$0.25+$0.62-$0.25$0.02 million$0.02 million
3/26/2025Q4 2024
Dyadic International, Inc. stock logo
DYAI
Dyadic International
-$0.04-$0.05-$0.01-$0.05$1.60 million$0.82 million
3/25/2025Q4 2024
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
-$5.10-$6.00-$0.90-$0.20$1.07 million$1.43 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
BioCardia, Inc. stock logo
BCDA
BioCardia
N/AN/AN/AN/AN/A
Dyadic International, Inc. stock logo
DYAI
Dyadic International
N/AN/AN/AN/AN/A
Outlook Therapeutics, Inc. stock logo
OTLK
Outlook Therapeutics
N/AN/AN/AN/AN/A
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BioCardia, Inc. stock logo
BCDA
BioCardia
N/A
1.78
1.78
Dyadic International, Inc. stock logo
DYAI
Dyadic International
1.54
5.15
5.15
Outlook Therapeutics, Inc. stock logo
OTLK
Outlook Therapeutics
N/A
0.32
0.64
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
1.26
4.89
4.80

Institutional Ownership

CompanyInstitutional Ownership
BioCardia, Inc. stock logo
BCDA
BioCardia
20.57%
Dyadic International, Inc. stock logo
DYAI
Dyadic International
27.95%
Outlook Therapeutics, Inc. stock logo
OTLK
Outlook Therapeutics
11.20%
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
72.03%

Insider Ownership

CompanyInsider Ownership
BioCardia, Inc. stock logo
BCDA
BioCardia
20.00%
Dyadic International, Inc. stock logo
DYAI
Dyadic International
29.50%
Outlook Therapeutics, Inc. stock logo
OTLK
Outlook Therapeutics
4.80%
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
2.37%
CompanyEmployeesShares OutstandingFree FloatOptionable
BioCardia, Inc. stock logo
BCDA
BioCardia
405.18 million3.67 millionOptionable
Dyadic International, Inc. stock logo
DYAI
Dyadic International
730.09 million21.07 millionOptionable
Outlook Therapeutics, Inc. stock logo
OTLK
Outlook Therapeutics
2033.57 million30.48 millionOptionable
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
805.79 million167.78 millionOptionable

Recent News About These Companies

X4 Pharmaceuticals Analyst Ratings
Earnings Preview For X4 Pharmaceuticals
Why X4 Pharmaceuticals, Inc. (XFOR) is Surging in 2025
X4 Pharmaceuticals trading halted, news pending
X4 Pharmaceuticals announces 1-for-30 reverse stock split
X4 Pharmaceuticals Announces Reverse Stock Split

New MarketBeat Followers Over Time

Media Sentiment Over Time

BioCardia stock logo

BioCardia NASDAQ:BCDA

$2.07 +0.10 (+5.08%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$2.08 +0.01 (+0.24%)
As of 05/27/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.

Dyadic International stock logo

Dyadic International NASDAQ:DYAI

$0.94 -0.06 (-5.60%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$0.96 +0.02 (+1.70%)
As of 05/27/2025 07:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health. The company offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial to demonstrate the safety in humans of a protein produced using the C1 platform. It has also developed the Dapibus thermophilic, a filamentous fungal-based microbial protein production platform to enable the development and large-scale manufacture of cost-effective proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, including food, nutrition, and wellness. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; license agreement with South Africa's Rubic One Health; Joint Development Agreement with a Global Food Ingredient Company; and sub-license agreement with Abic Biological Laboratories Ltd., Alphazyme, LLC, and Abic Biological Laboratories Ltd. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.

Outlook Therapeutics stock logo

Outlook Therapeutics NASDAQ:OTLK

$1.61 +0.01 (+0.63%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$1.56 -0.05 (-3.35%)
As of 05:48 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

X4 Pharmaceuticals stock logo

X4 Pharmaceuticals NASDAQ:XFOR

$3.39 +0.29 (+9.35%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$3.43 +0.04 (+1.18%)
As of 04:56 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.